Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 124

Results For "portfolio"

1726 News Found

Advent International launches Cohance Lifesciences
News | November 02, 2022

Advent International launches Cohance Lifesciences

API platform to comprise of RA Chem Pharma, ZCL Chemicals and Avra Laboratories


Jubilant Ingrevia to invest Rs. 2,050 crore during FY 22-25
News | November 01, 2022

Jubilant Ingrevia to invest Rs. 2,050 crore during FY 22-25

Most of the new growth Capex investments are happening on the Specialty Chemicals and Nutrition side


Glenmark Pharmaceuticals launches Fingolimod Capsules in US
News | November 01, 2022

Glenmark Pharmaceuticals launches Fingolimod Capsules in US

According to IQVIA sales data for the 12-month period ending September 2022, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately US $1.8 billion


Granules India plans H2 FY 2022-23 R&D spend in Rs. 80-90 Cr
News | October 30, 2022

Granules India plans H2 FY 2022-23 R&D spend in Rs. 80-90 Cr

The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track


Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr
News | October 27, 2022

Gland Pharma’s Q2 FY23 revenue stood at Rs. 1,044.4 Cr

Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr


Lupin to acquire two inhalation brands from Sunovion for US$75 million
News | October 20, 2022

Lupin to acquire two inhalation brands from Sunovion for US$75 million

The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.


Aster Pharmacy enters KSA in partnership with Al Hokair Holding Group
News | October 18, 2022

Aster Pharmacy enters KSA in partnership with Al Hokair Holding Group

Both the partners will work towards bringing Aster Pharmacy’s in-house quality care products to serve the healthcare needs of the local population in KSA


RPG Life Sciences Q2 FY23 revenue up 20%; PBT up 21%
News | October 18, 2022

RPG Life Sciences Q2 FY23 revenue up 20%; PBT up 21%

In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs


Biocon Biologics signs licensing agreement with Yoshindo
News | October 17, 2022

Biocon Biologics signs licensing agreement with Yoshindo

Yoshindo gets exclusive commercialization rights in Japan for bUstekinumab and bDenosumab developed and manufactured by Biocon Biologics


DKSH acquires two ear care brands
News | October 14, 2022

DKSH acquires two ear care brands

DKSH has signed an agreement to acquire two ear care brands from Noru Pharma for Australia, New Zealand, and selected markets in Asia.